REFERENCES

• SahaS.ChantD.WelhamJ.McGrathJ.A systematic review of the prevalence of schizophrenia.PLoS Med.20052e14115916472
   PubMed Web of Science ®Google Scholar
• GoffDC.GatherC.EvinsAE.HendersonDC.et al.Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.J Clin Psychiatry.20056618319415705003
   PubMed Web of Science ®Google Scholar
• PalmerBW.HeatonRK.GladsjoJA.et al.Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving.Schizophr Res.20025520521512048144
   PubMed Web of Science ®Google Scholar
• World Health Organization.World Health Report 2001: new understanding, new hope. Geneva: World Health Organization,2001
   Google Scholar
• MurrayCJL.LopezAD.The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press;1996
   Google Scholar
• World Health Organization,international Classification of Functioning, Disability and Health- ICF. Geneva, Switzerland: World Health Organization,2001
   Google Scholar
• LiebermanJA.StroupTS.McEvoyJP.et al.Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med.20053531209122316172203
   PubMed Web of Science ®Google Scholar
• JonesPB.BarnesTR.DaviesL.et al.Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).Arch Gen Psychiatry.2006631079108717015810
   PubMed Web of Science ®Google Scholar
• KahnRS.FleischhackerWW.BoterH.et al.EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.Lancet.20083711085109718374841
   PubMed Web of Science ®Google Scholar
• KaneJM.Treatment adherence and long-term outcomes.CNS Spectr.200712(10suppl 17)212617934386
   PubMed Web of Science ®Google Scholar
• RobinsonD.WoernerMG.AlvirJMJ.et al.Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.Arch Gen Psychiatry.19995624124710078501
   PubMed Web of Science ®Google Scholar
• WeidenPJ.OlfsonM.Cost of relapse in schizophrenia.Schizophr Bull.1995214194297481573
   PubMed Web of Science ®Google Scholar
• CorrellCU.Balancing efficacy and safety in treatment with antipsychotics.CNS Spectr.200712(10 suppl 17)122017934385
   PubMed Web of Science ®Google Scholar
• RobinsonDG.WoernerMG.AlvirJM.BilderRM.HinrichsenGA.LiebermanJA.Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.Schizophr Res.20025720921912223252
   PubMed Web of Science ®Google Scholar
• TandonR.BelmakerRH.GattazWF.et al.World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.Schizophr Res.2008100203818243663
   PubMed Web of Science ®Google Scholar
• CaseyDE.Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.Schizophr Res.199141091201674881
   PubMed Web of Science ®Google Scholar
• KaneJM.WoernerM.LiebermanJ.Tardive dyskinesia: prevalence, incidence, and risk factors.J Clin Psychopharmacol.19888(4 suppl)52S56S3065365
   PubMed Web of Science ®Google Scholar
• JesteDV.CaligiuriMP.Tardive dyskinesia.Schizophr Bull.1993193033158100643
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumH.ZhuB.FariesD.PengX.KinonBJ.TohenM.Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.J Clin Psychiatry.2008691580158819192441
   PubMed Web of Science ®Google Scholar
• LehmanAF.LiebermanJA.DixonLB.et al.American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition.Am J Psychiatry.2004161(2suppl)15615000267
   PubMed Web of Science ®Google Scholar
• KaneJM.Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.J Clin Psychiatry.200465 suppl 91620. Review15189107
   PubMed Web of Science ®Google Scholar
• CorrellCU.LeuchtS.KaneJM.Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.Am J Psychiatry.200416141442514992963
   PubMed Web of Science ®Google Scholar
• KaneJM.FleischhackerWW.HansenL.PerlisR.PikalovA 3rd.Assunçâo-TalbottS.Akathisia: an updated review focusing on second-generation antipsychotics.J Clin Psychiatry.20097062764319389331
   PubMed Web of Science ®Google Scholar
• LeuchtS.WahlbeckK.HamannJ.KisslingW.New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.Lancet.20033611581158912747876
   PubMed Web of Science ®Google Scholar
• Millerdel D.CaroffSN.DavisSM.et al.Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Extrapyramidal side-effects of antipsychotics in a randomised trial.Br J Psychiatry.200819327928818827289
   PubMed Web of Science ®Google Scholar
• LeuchtS.CorvesC.ArbterD.EngelRR.LiC.DavisJM.Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis.Lancet.2009373314119058842
   PubMed Web of Science ®Google Scholar
• KapurS.MatnoD.Half a century of antipsychotics and still a central role for dopamine D2 receptors.Prog Neuropsychopharmacol Biol Psychiatry.2003271081109014642968
   PubMed Web of Science ®Google Scholar
• ParsonsB.AllisonDB.LoebelA.WilliamsK.GillerE.RomanoS.SiuC.Weight effects associated with antipsychotics: a comprehensive database analysis.Schizophr Res.200911010311019321312
   PubMed Web of Science ®Google Scholar
• KaneJM.BarrettEJ.CaseyDE.CorrellCU.GelenbergAJ.KleinS.NewcomerJW.Metabolic effects of treatment with atypical antipsychotics.J Clin Psychiatry.2004651447145515554755
   PubMed Web of Science ®Google Scholar
• AllisonDB.MentoreJL.HeoM.ChandlerLP.CappelleriJC.InfanteMC.WeidenPJ.Antipsychotic-induced weight gain: a comprehensive research synthesis.Am J Psychiatry.1 9991561686169610553730
   PubMed Web of Science ®Google Scholar
• AllisonDB.NewcomerJW.DunnAL.et al.Obesity among those with mental disorders: a National Institute of Mental Health meeting report.Am JPrevMed.200936341350
   PubMed Web of Science ®Google Scholar
• CorrellCU.Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.Int Rev Psychiatry.20082019520118386212
   PubMed Web of Science ®Google Scholar
• TenbackDE.van HartenPN.SlooffCJ.van OsJ.Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.Am J Psychiatry.20061631438144016877660
   PubMed Web of Science ®Google Scholar
• KapurS.BarlowK.VanderSpekSC.JavanmardM.NobregaJN.Druginduced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo.Psychopharmacology (Berl).200115716817111594441
   PubMed Web of Science ®Google Scholar
• NevilleMJ.JohnstoneEC.WaltonRT.Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1.Hum Mutat.20042354054515146457
   PubMed Web of Science ®Google Scholar
• ThompsonJ.ThomasN.SingletonA.et al.D2 dopamine receptor gene (DRD2) TaqIA polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.Pharmacogenetics.199774794849429233
   PubMedGoogle Scholar
• PohjalainenT.RinneJO.NâgrenK.et al.The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.Mol Psychiatry.199832562609672901
   PubMed Web of Science ®Google Scholar
• ZaiCC.De LucaV.HwangRW.et al.Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.Mol Psychiatry.20071279479517767146
   PubMed Web of Science ®Google Scholar
• BakkerPR.van HartenPN.van OsJ.Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1 A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Mol Psychiatry.20081354455618180754
   PubMed Web of Science ®Google Scholar
• LererB.SegmanRH.FangerauH.et al.Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.Neuropsychopharmacology.20022710511912062911
   PubMed Web of Science ®Google Scholar
• BakkerPR.van HartenPN.van OsJ.Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.Schizophr Res.20068318519216513329
   PubMed Web of Science ®Google Scholar
• TsaiHT.NorthKE.WestSL.PooleC.The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta-analysis.Am J Med Genet B Neuropsychiatr Genet.2009 Apr 8. [Epub ahead of print]
   Web of Science ®Google Scholar
• LererB.SegmanRH.TanEC.et al.Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.Int J Neuropsychopharmacol.2005841142515857569
   PubMed Web of Science ®Google Scholar
• PatsopoulosNA.NtzaniEE.ZintzarasE.loannidisJP.CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.Pharmacogenet Genomics.20051515115815861039
   PubMed Web of Science ®Google Scholar
• SchwartzJC.DiazJ.PilonC.SokoloffP.Possible implications of the dopamine D receptor in schizophrenia and in antipsychotic drug actions.Brain Res Brain Res Rev20003127728710719154
   PubMed Web of Science ®Google Scholar
• SchwartzJC.LevesqueD.MartresMP.SokoloffP.Dopamine D3 receptor: basic and clinical aspects.Clin Neuropharmacol.1993162953148104095
   PubMed Web of Science ®Google Scholar
• LundstromK.TurpinMP.Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki forest virus system.Biochem Biophys Res Commun.199623225:10681072
   Google Scholar
• JeanneteauF.FunalotB.JankovicJ.et al.Afunctional variant of the dopamine D3 receptor is associated with risk and age-at- onset of essential tremor.Proc Natl Acad Sci USA.2006:11103107531075816809426
   PubMed Web of Science ®Google Scholar
• ShaikhS.CollierDA.ShamPC.et al.Allelic association between a Ser9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.Hum Genet.1996977147198641685
   PubMed Web of Science ®Google Scholar
• ScharfetterJ.ChaudhryHR.HornikK.et al.Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients.Eur Neuropsychopharmacol.199910172010647091
   PubMed Web of Science ®Google Scholar
• SzekeresG.KériS.JuhâszA.et al.Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.Am J Med Genet B Neuropsychiatr Genet.20041241514681904
   PubMedGoogle Scholar
• LaneHY.HsuSK.LiuYC.ChangYC.HuangCH.ChangWH.Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.J Clin Psychopharmacol.20052561115643094
   PubMed Web of Science ®Google Scholar
• MalhotraAK.GoldmanD.BuchananRW.et al.The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.Mol Psychiatry.1998372759491816
   PubMed Web of Science ®Google Scholar
• XuanJ.ZhaoX.HeG.YuL.et al.Effects of the dopamine D Receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study.Neuropsychopharmacoiogy.200833305311
   PubMed Web of Science ®Google Scholar
• XiaoR.BoehnkeM.Quantifying and correcting for the winner's curse in genetic association studies.Genet Epidemiol.20093345346219140131
   PubMed Web of Science ®Google Scholar
• TsaiHT.CaroffSN.MillerDD.et al.A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial.Am J Med Genet B Neuropsychiatr Genet.2009 May 27. [Epub ahead of print]
   Web of Science ®Google Scholar
• MànnistôPT.UlmanenI.LundstrômK.et al.Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors.Prog Drug Res.1992392913501475365
   PubMedGoogle Scholar
• LachrnanHM.PapolosDF.SaitoT.YuYM.SzumlanskiCL.WeinshilboumRM.Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatrie disorders.Pharmacogenetics.199662432508807664
   PubMedGoogle Scholar
• FardeL.NybergS.OxenstiernaG.NakashimaY.HalldinC.EricssonB.Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidonetreated schizophrenic patients.J Clin Psychopharmacol.19951519S23S7537284
   PubMed Web of Science ®Google Scholar
• KapurS.ZipurskyRB.RemingtonG.et al.5- HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.Am J Psychiatry.19981559219289659858
   PubMed Web of Science ®Google Scholar
• RasmussenK.AghajanianGK.Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.Neuropsychopharmacoiogy.19881101107
   PubMed Web of Science ®Google Scholar
• TrichardC.Paillère-MartinotML.Attar-LevyD.RecassensC.MonnetF.MartinetJL.Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.Am J Psychiatry.19981555055089545996
   PubMed Web of Science ®Google Scholar
• ArranzMJ.MunroJ.ShamP.et al.Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.Schizophr Res.19983293999713904
   PubMed Web of Science ®Google Scholar
• MyersRL.AireyDC.ManierDH.SheltonRC.Sanders-BushE.Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression.Biol Psychiatry.20076116717316697352
   PubMed Web of Science ®Google Scholar
• WaeberC.PalaciosJM.Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia.Brain Res Mol Brain Res.1994241992097968358
   PubMedGoogle Scholar
• BishopC.TessmerJL.UllrichT.RiceKC.WalkerPD.Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopaminedepleted rats by intrastriatal 5-HT2A/2C agonism.J Pharmacol Exp Ther.200431068769415044557
   PubMed Web of Science ®Google Scholar
• CacciaS.New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.Curr Opin Investig Drugs.2002310731080
   PubMedGoogle Scholar
• BertilssonL.DahlML.DalénP.Al-ShurbajiA.Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.Br J Clin Pharmacol.20025311112211851634
   PubMed Web of Science ®Google Scholar
• KobyleckiCJ.JakobsenKD.HansenT.JakobsenIV.RasmussenHB.WergeT.CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Neuropsychobiology.20095922222619521114
   PubMed Web of Science ®Google Scholar
• EichhammerP.AlbusM.Borrmann-HassenbachM.et al.Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.Am J Med Genet.20009618711910893495
   PubMed Web of Science ®Google Scholar
• GunesA.ScordoMG.JaansonP.DahlML.Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.Psychopharmacology (Berl).200719047948417102980
   PubMed Web of Science ®Google Scholar
• GuzeyC.ScordoMG.SpinaE.LandsemVM.SpigsetO.Antipsychoticinduced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.Eur J Clin Pharmacol.20076323324117225991
   PubMed Web of Science ®Google Scholar
• GassôP.MasS.BernardoM.AlvarezS.ParelladaE.LafuenteA.A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.Pharmacogenomics J.2009940441019506579
   PubMed Web of Science ®Google Scholar
• GreenbaumL.StrousRD.KanyasK.et al.Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.Pharmacogenet Genomics.20071751952817558307
   PubMed Web of Science ®Google Scholar
• GreenbaumL.SmithRC.RigbiA.et al.Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region.Pharmacogenomics J.2009910311018347610
   PubMed Web of Science ®Google Scholar
• Al HadithyAF.WilffertB.BruggemanR.et al.Lack of association between antipsychotic-induced Parkinsonism or its subsyrnptorns and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.Hum Psychopharmacol.20092412312819156702
   PubMed Web of Science ®Google Scholar
• CalargeCA.EllingrodVL.AcionL.et al.Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Pharmacogenet Genomics.20091937338219339912
   PubMed Web of Science ®Google Scholar
• KwonJS.KimE.KangDH.ChoiJS.YuKS.JangIJ.ShinSG.APLUS study group. TaqlA polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. furNeuropsychopharmacol.200818897907
   Web of Science ®Google Scholar
• Yasui-FurukoriN.SaitoM.TsuchimineS.et al.Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.Prog Neuropsychopharmacol Biol Psychiatry.2008321491149518579277
   PubMed Web of Science ®Google Scholar
• AklilluE.KalowW.EndrenyiL.HarperP.MiuraJ.OzdemirV.CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.Pharmacogenet Genomics.20071798999318075468
   PubMed Web of Science ®Google Scholar
• AndersonGM.ScahillL.McCrackenJT.et al.Effects of short- and longterm risperidone treatment on prolactin levels in children with autism.Biol Psychiatry20076154555016730335
   PubMed Web of Science ®Google Scholar
• YoungRM.LawfordBR.BarnesM.et al.Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.Br J Psychiatry.200418514715115286066
   PubMed Web of Science ®Google Scholar
• MiharaK.KondoT.SuzukiA.et al.Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to TaqlA polymorphism of DRD2 gene.Psychopharmacology (Berl).200014924625010823405
   PubMed Web of Science ®Google Scholar
• ComptonMT.MillerAH.Antipsychotic-induced hyperprolactinemia and sexual dysfunction.Psychopharmacol Bull .20023614316412397853
   PubMedGoogle Scholar
• ReynoldsGP.Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.J Psychopharmacol.20041834034515358977
   PubMedGoogle Scholar
• AdanRA.VanderschurenLJ.la FleurSE.Anti-obesity drugs and neural circuits of feeding.Trends Pharmacol Sci.20082920821718353447
   PubMed Web of Science ®Google Scholar
• DavisR.FauldsD.Dexfenf luramine. An updated review of its therapeutic use in the management of obesity.Drugs.1996526967249118819
   PubMed Web of Science ®Google Scholar
• ReynoldsGP.ZhangZJ.ZhangXB.Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism.Lancet.20023592086208712086765
   PubMed Web of Science ®Google Scholar
• MillerDD.EllingrodVL.HolmanTL.BuckleyPF.ArndtS.Clozapineinduced weight gain associated with the 5HT2C receptor -759C/T polymorphism.Am J Med Genet.20051339710015635667
   PubMedGoogle Scholar
• ReynoldsGP.ZhangZ.ZhangX.Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.Ami J Psychiatry.2003160677679
   PubMed Web of Science ®Google Scholar
• EllingrodVL.PerryPJ.RingoldJC.et al.Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.Am J Med Genet. B Neuropsychiatr Genet.200534767815666332
   PubMedGoogle Scholar
• TemplemanLA.ReynoldsGP.ArranzB.SanL.Polymorphisms of the 5HT2C receptor and leptin genes are associated with antipsychotic druginduced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenet Genomics.20051519520015864111
   PubMedGoogle Scholar
• LaneHY.LiuYC.HuangCL.et al.Risperidone-related weight gain: genetic and nongenetic predictors.J Clin Psychopharmacol.20062612813416633140
   PubMed Web of Science ®Google Scholar
• RyuS.ChoEY.ParkT.-759 QT polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.Prog Neuropsychopharmacol Biol Psychiatry.20073167367717275977
   PubMed Web of Science ®Google Scholar
• TsaiSJ.HongCJ.YuYW.LinCH.-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.Lancet.2002360179012480466
   PubMed Web of Science ®Google Scholar
• BasileVS.MasellisM.De LucaV.MeltzerHY.KennedyJL.759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.Lancet.20023601790179112480467
   PubMed Web of Science ®Google Scholar
• TheisenFM.HinneyA.BrômelT.et al.Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals.Psychiatr Genet.20041413914215318026
   PubMed Web of Science ®Google Scholar
• ReynoldsGP.TemplemanLA.ZhangZJ.The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.Prog Neuropsychopharmacol Biol Psychiatry.2005291021102815953671
   PubMed Web of Science ®Google Scholar
• RosskopfD.BuschS.MantheyI.SiffertW.G protein beta 3 gene: structure, promoter, and additional polymorphisms.Hypertension.200036334110904009
   PubMed Web of Science ®Google Scholar
• SiffertW.G-protein beta3 subunit 825T allele and hypertension.Curr Hypertens Rep.20035475312530935
   PubMed Web of Science ®Google Scholar
• SouzaRP.De LucaV.MuscettolaG.et al.Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis.Prog Neuropsychopharmacol Biol Psychiatry.2008321848185318793692
   PubMed Web of Science ®Google Scholar
• erlisRH.GanzDA.AvornJ.Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.Clin Psychopharmacol.200525427434
   PubMed Web of Science ®Google Scholar
• ConleyRR.KellyDL.Management of treatment resistance in schizophrenia.Biol Psychiatry.20015089891111743944
   PubMed Web of Science ®Google Scholar
• LenczT.MorganTV.AthanasiouM.et al.Converging evidence for a pseudoautosotnal cytokine receptor gene locus in schizophrenia.Mol Psychiatry.20071257258017522711
   PubMed Web of Science ®Google Scholar
• OsterfieldM.EgelundR.YoungLM.FlanaganJG.Interaction of amyloid precursor protein with contactins and NgCAM in the retinotectal system.Development.20081351189119918272596
   PubMed Web of Science ®Google Scholar
• RoohiJ.MontagnaC.TegayDH.et al.Disruption of contactin 4 in three subjects with autism spectrum disorder.J Med Genet.20094617618218349135
   PubMed Web of Science ®Google Scholar
• icchioniMM.MurrayRM.Schizophrenia.BMJ.2007335919517626963
   PubMedGoogle Scholar
• LarsenTK.FriisS.HaahrU.et al.Early detection and intervention in first-episode schizophrenia: a critical review.Acta Psychiatr Scand.200110332333411380302
   PubMed Web of Science ®Google Scholar
• MelleI.LarsenTK.HaahrU.et al.Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis.Arch Gen Psychiatry.20086563464018519821
   PubMed Web of Science ®Google Scholar
• LenczT.RobinsonDG.XuK.et al.DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in firstepisode schizophrenia patients.Am J Psychiatry.200616352953116513877
   PubMed Web of Science ®Google Scholar